Adam Dubow Biography and Net Worth

Adam Dubow serves as Senior Vice President, Chief Compliance Officer and Ethics Officer of the Company. 2013 to 2015 – Vice President and Assistant General Counsel, China, Japan and Intercon Region and EMAC Region 2015 to 2018 – Vice President and Associate General Counsel, Research and Development 2018 to present – Senior Vice President, Chief Compliance and Ethics Officer.

What is Adam Dubow's net worth?: The estimated net worth of Adam Dubow is at least $812,665.00 as of February 16th, 2024. Mr. Dubow owns 16,585 shares of Bristol-Myers Squibb stock worth more than $812,665 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Dubow may own. Learn More about Adam Dubow's net worth.
How do I contact Adam Dubow?: The corporate mailing address for Mr. Dubow and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on Adam Dubow's contact information.
Has Adam Dubow been buying or selling shares of Bristol-Myers Squibb?: Adam Dubow has not been actively trading shares of Bristol-Myers Squibb during the last ninety days. Most recently, Adam Dubow sold 3,119 shares of the business's stock in a transaction on Wednesday, May 5th. The shares were sold at an average price of $64.21, for a transaction totalling $200,270.99. Following the completion of the sale, the senior vice president now directly owns 16,243 shares of the company's stock, valued at $1,042,963.03. Learn More on Adam Dubow's trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. During the last year, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 69,103 shares worth more than $4,525,215.08. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 12/5/2023.

Adam Dubow Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/5/2021	Sell	3,119	$64.21	$200,270.99	16,243
11/24/2020	Sell	900	$63.39	$57,051.00	15,186
5/22/2020	Sell	3,200	$61.01	$195,232.00	16,086

Adam Dubow Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $49.00

$48.12

$49.01

50 Day Range

MA: $51.25

$47.83

$54.40

2 Week Range

Now: $49.00

$47.58

$70.93

Volume

5,810,076 shs

Average Volume

15,646,320 shs

Market Capitalization

$99.31 billion

P/E Ratio

12.69

Dividend Yield

5.02%

Beta

0.39

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report